.STUDY HIGHLIGHT.16 Oct 2024.
In the NIAGARA litigation, the enhancement of perioperative durvalumab to common therapy for muscle-invasive bladder cancer improved event-free as well as in general survival, noting a brand new treatment alternative for this condition.